Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
154 hedge funds and large institutions have $1.49B invested in Chinook Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 57 increasing their positions, 46 reducing their positions, and 18 closing their positions.
207% more call options, than puts
Call options by funds: $969K | Put options by funds: $316K
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
33% more capital invested
Capital invested by funds: $1.12B → $1.49B (+$366M)
24% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 46
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
2% more funds holding
Funds holding: 151 → 154 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$16.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$16M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$11.5M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$10.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$26M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$12M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$9.02M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$5.08M |
| 5 |
HM
HealthCor Management
New York
|
-$4.58M |
KDNY Hedge Fund Activity: Q4 2022 in Review
154 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q4 2022, worth a combined $1.49B — up 33% from $1.12B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new KDNY positions and 18 closed out — a net gain of 4 holders — while 57 added to existing stakes and 46 trimmed.
The largest buyer was Federated Hermes, adding an estimated $16.6M. The largest seller was Point72 Asset Management, cutting an estimated $26M.
- 154 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q4 2022, up from 151 in Q3 2022.
- Funds reported $1.49B of Chinook Therapeutics, Inc. Common Stock stock for Q4 2022, up 33% quarter-over-quarter.
- 22 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q4 2022 and 18 closed out, a net change of +4 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q4 2022 was Federated Hermes, an estimated $16.6M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q4 2022 was Point72 Asset Management, an estimated $26M sold.
Based on aggregated 13F filings for Q4 2022.